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INTRODUCTION
Early detection and novel systemic adjuvant therapy strate-
gies have considerably improved the survival of breast cancer 
patients [1,2]. As chemotherapy in the adjuvant setting known 
to contribute to significant progress in the management of 
breast cancer [1], it is imperative to examine the possible im-
pact of chemotherapy on the quality of life (QOL) of breast 
cancer patients and provide information about adverse effects 
of chemotherapy from the acute phase of treatment to ongo-
ing survivorship.
Many studies have been conducted on the impact of sur-
gery method on QOL and psychological distress of women 
with breast cancer; however, few have investigated the impact 
of adjuvant chemotherapy on overall QOL of women with 
breast cancer. Previous research indicated that QOL variables 
including emotional functioning, anxiety, and depression, 
mood, well-being, and distress have not differed by surgery 
method with the exception of daily disruption [2-8]. 
Adjuvant chemotherapy is reported to partially influence 
QOL during or after the treatment period [9-11]. However, 
earlier studies on the impact of chemotherapy are controver-
sial based on the survival time, as some studies reported that 
chemotherapy was not a significant predictor of QOL during 
the first year after diagnosis [8,12,13], while the statistically 
significant negative association of past chemotherapy with 
current QOL was found in long-term survivors at least 5 years 
since diagnosis not only in sexual functioning but in other 
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 Purpose: The aims of this cross-sectional study were to explore 
and evaluate the impact of adjuvant chemotherapy on quality of 
life in breast cancer patients according to the survival time from 
surgery. Methods: Completed questionnaires were collected from 
534 women with breast cancer. Clinical and sociodemographic 
characteristics were reviewed and Functional Assessment of 
Cancer Therapy-Breast cancer instrument, global quality of life, 
Beck Depression Inventory, and unmet sexuality needs were ad-
ministered. Descriptive statistics, t-tests, chi-square tests and 
multiple analysis of covariance were performed while controlling 
for confounding variables. Results: Statistically significant differ-
ences were found between chemotherapy and no chemotherapy 
group on depression (p=0.026), unmet sexuality needs (p=
0.010), breast cancer specific concerns (p=0.010), physical well-
being (p=0.001), and emotional well-being (p=0.028). Chemo-
therapy effects also varied according to survival time since sur-
gery such as for group 1 (<1 year since surgery), significant dif-
ferences were found on Beck Depression Inventory (p=0.042), 
unmet sexuality needs (p=0.016), breast cancer subscale 
(p=0.004), and physical well-being (p=0.016) and for group 3 
(>3 years since surgery) on depression (p=0.019) and physical 
well-being (p=0.028) respectively; however, there were no signifi-
cant differences between chemotherapy and no chemotherapy 
group for group 2 (1-3 years since surgery). Conclusion: As ex-
pected, breast cancer patients who underwent adjuvant chemo-
therapy experienced significantly worse quality of life than those 
who did not receive chemotherapy. Furthermore, the adverse 
chemotherapy effects on the quality of life appear to vary ac-
cording to the time since surgery. These results suggest that 
health care professionals may need to address long-term as well 
as short-term chemotherapy side-effects and intervene accord-
ingly to enhance quality of life of breast cancer patients.
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general QOL aspects including physical and social function-
ing as well as general health [2]. Contrary to this, Joly et al. 
[11] did not find any evidence of adjuvant chemotherapy im-
pairing long-term QOL or social life in women with pre-
menopausal node-negative women with breast cancer.
Therefore, this cross-sectional study was conducted with two 
objectives: to evaluate the impact of adjuvant chemotherapy by 
comparing QOL between breast cancer patients receiving 
chemotherapy and those not receiving chemotherapy and to 
examine the impact of adjuvant chemotherapy according to 
survival time since surgery.
METHODS
Patients
The subjects were from a consecutive sample of outpatients 
diagnosed with breast cancer at the Yonsei University Severance 
Hospital Breast Cancer Clinic [14] and attending regular fol-
low-up appointments postsurgery. The participants were en-
rolled based on the following inclusion criteria: 1) age be-
tween 20 and 80 years, 2) stage I, II, and III cancer, 3) no evi-
dence of systemic metastasis, and 4) no evidence of psychosis, 
dementia, or suicidal behavior. Among the 1,250 eligible pa-
tients who consented to participate in the study, 1,084 re-
turned the survey. In this portion of the study, we retrieved 
the data of 771 patients who underwent surgery at least 1 
month previously and had not received chemotherapy prior 
to surgery. Also, the data from the participants who did not 
respond to survey questions more than 10% of the total re-
sponses were excluded because missing data more than 10% 
of the total responses could influence the results of signifi-
cance tests [15]. Finally, a total of 534 patients were included 
in the study. The study was approved by the Institutional Re-
view Board of the Yonsei University Severance Hospital (4-
2009-0269).
Measures
Sociodemographic and clinical backgrounds
Sociodemographic variables such as age, education, current 
marital status, employment and economic status were includ-
ed in the survey. The treatment variables were collected by re-
viewing the medical records of each patient which include 
TNM stage, surgery method, hormone therapy, radiation 
therapy, survival time since surgery. Questions about men-
struation status and performance status were also included in 
the survey. The performance status was measured with the 
Eastern Cooperative Oncology Group Performance Status 
(ECOG-PS) scale which assesses the level of functioning based 
on activity, ambulatory status and need for care ranging from 
grade 0 (normal activity) to grade 4 (completely bedridden). 
ECOG-PS is widely used and well validated [16]. 
Functional Assessment of Cancer Therapy-Breast cancer
Health-related QOL was measured with the Functional 
Assessment of Cancer Therapy-Breast cancer (FACT-B) ver-
sion 4 which comprises of 36-items to measure both the 27-
item general QOL associated with cancer (FACT-G) and the 
additional 9-item breast cancer related QOL, breast cancer 
subscale (BCS). The subscales of FACT-G are physical well-
being (PWB), functional well-being (FWB), emotional well-
being (EWB), and social/family well-being (SWB). The psy-
chometric properties of the FACT-B are well documented [17] 
and validated in Korean population [18]. The test was con-
ducted and scored in accordance with the instructions of the 
version 4 provided by the Functional Assessment of Chronic 
Illness Therapy (FACIT) Measurement System (www.facit.
org). A total FACT-B score is calculated by summing the sub-
scales. The instrument asks respondents to rate how true each 
statement is for the last 7 days with a response scale ranging 
from 0 (not at all) to 4 (very much). Cronbach α was 0.79 to 
0.90 in the Korean version of FACT-B [18] and Cronbach α in 
this study was 0.852 for PWB, 0.855 for SWB, 0.808 for EWB, 
0.914 for FWB and 0.702 for BCS.
Global QOL
The overall QOL of the patients was assessed using the Lad-
der of Life, a single-item measure. The respondents are asked 
to circle the number that represents how they feel at the pre-
sent time. One represents the worst possible life and 10 repre-
sents the best possible life, Ladder of Life is widely used scale 
and provides a good summary of QOL [19].
The unmet sexuality needs
The unmet sexuality needs of breast cancer patients were 
assessed with the sexuality needs domain of the supportive 
care needs survey (SCNS). SCNS was designed to provide di-
rect assessment of cancer patients’ perceived needs for help 
and identify the magnitude of need for help [20]. The partici-
pants were asked to indicate their level of the need ranging 
from 1 ‘no need (not applicable)’ to 5, ‘high need’ for help over 
the last month in relation to having cancer and a higher score 
indicated a higher perceived unmet need. The survey’s psy-
chometric properties and the reliability as well as the validity 
of this measurement have been well documented [20]. In the 
present study, SCNS-LF59 survey was used in Korean, which 
had been translated and back-translated by Hwang and Park 
[21]. The sexuality needs subscale was consisted of 3 items: 1) 
changes in sexual feelings, 2) changes in sexual relationships, 
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and 3) to be given information about sexual relationships. The 
reliability coefficient of the subscale was found to be 0.913 in 
this study.
The Beck Depression Inventory
The Beck Depression Inventory (BDI) is one of the most 
commonly used self-rated depression symptom question-
naires in medical settings. BDI is a 21-item inventory that de-
scribes symptoms and attitudes. Each item in BDI describes a 
particular aspect of depression and consists of four self-evalu-
ative statements. The study participants are asked to circle the 
item that best describes their feelings in the last week. The 
Korean version of the BDI was standardized [22] and its val-
idity and reliability have been established [23]. The reliability 
coefficient for BDI was 0.909 in this study.
Statistical analysis
To explore the effects of adjuvant chemotherapy (indepen-
dent variable) on health related QOL, global QOL, depression 
and unmet sexuality needs (dependent variables), multiple 
analysis of covariance (MANCOVA) was performed after 
controlling confounding variables (covariates). Since depen-
dent variables of the study including health related QOL, 
global QOL, depression and unmet sexuality needs were sig-
nificantly correlated with each other, MANCOVA was consid-
ered as appropriate for the analysis. First, sociodemographic 
and clinical variables were analyzed using descriptive statistics 
including mean, standard deviation, number and percentage. 
Then, both independent t-tests for continuous variables and 
chi-square tests for categorical variables were conducted to 
identify confounding variables between women who had re-
ceived chemotherapy after surgery and those who had not. 
Data analyses were performed using SPSS version 20.0 statis-
tical program (IBM, Armonk, USA)
RESULTS
Sociodemographic and clinical characteristics of the 
participants
Sociodemographic and clinical characteristics of the partici-
pants are shown in Tables 1 and 2. Among a total of 534 women, 
about 69% of the participants received chemotherapy after 
surgery for breast cancer. Participants were classified based on 
the time since surgery such as <1 year, group 1; 1 to 3 years, 
group 2; and >3 years, group 3. One hundred seventeen, 108, 
and 144 participants received chemotherapy after surgery 
among 198, 152, and 184 participants in group 1, 2, and 3, re-
spectively (data not shown). Homogeneity tests between 
women receiving chemotherapy and women not receiving 
chemotherapy showed significant differences in performance 
status (p=0.032), TNM stage (p<0.001), hormone therapy 
Table 1. Sociodemographic characteristics of the participants (n=534)
Characteristic
Chemotherapy
p-valueDone (n=369)
No. (%)
None (n=165)
No. (%)
Age (yr)* 48.2±8.4 48.8±8.9 0.406
Education level 0.193
   <High school 49 (13.3) 15 (9.1)
    High school 189 (51.2) 80 (48.5)
   >High school 131 (35.5) 70 (42.4)
Marital status 0.876
   Single/Separated 36 (9.8) 17 (10.3)
   Married/Partnered 333 (90.2) 148 (89.7)
Employment 0.203
   Employed 122 (33.1) 64 (38.7)
   Unemployed 247 (66.9) 101 (61.3)
Perceived financial status 0.990
   High 38 (10.3) 17 (10.3)
   Middle 268 (72.6) 119 (72.1)
   Low 63 (17.1) 29 (17.6)
*Mean±SD.
Table 2. Clinical characteristics of the participants (n=534)
Characteristic
Chemotherapy
p-valueDone (n=369)
No. (%)
None (n=165)
No. (%)
Menstruation status 0.622
   Absent 246 (66.7) 106 (64.2)
   Present 123 (33.3) 59 (35.8)
TNM stage <0.001
   0 or I 130 (35.2) 147 (89.1)
   II 197 (53.4) 18 (10.9)
   III 42 (11.4) 0 (0)
Surgery method 0.264
   Total mastectomy 204 (55.3) 80 (48.5)
   Breast-conserving surgery 165 (44.7) 85 (51.5)
Hormone therapy 0.039
   Done 254 (68.8) 128 (77.6)
   None 115 (31.2) 37 (22.4)
Radiation therapy 0.301
   Done 207 (56.1) 84 (50.9)
   None 162 (43.9) 81 (49.1)
Time since surgery (yr) <0.001
   <1 117 (31.7) 81 (49.1)
   1-3 108 (29.3) 44 (26.7)
   >3 144 (39.0) 40 (24.2)
ECOG-PS 0.032
   0 222 (60.2) 118 (71.5)
   1 132 (35.8) 44 (26.7)
   ≥ 2 15 (4.0) 3 (1.8)
ECOG-PS=Eastern Cooperative Oncology Group Performance Status.
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(p=0.039), and time since surgery (p<0.001). 
Effects of chemotherapy on depression, unmet sexuality 
needs, global QOL, and QOL
The effects of adjuvant chemotherapy on depression, sexual-
ity needs, global QOL and health related QOL among women 
with breast cancer are shown in Figure 1. Based on the results 
on descriptive statistics and homogeneity tests, variables in-
cluding performance scale, hormone therapy, TNM stage, and 
time since surgery were identified as confounding variables. 
Hence, MANCOVA with covariates of performance scale, 
hormone therapy, TNM stage, and time since surgery were 
conducted. The patients who underwent chemotherapy expe-
rienced statistically significant impact on depression (F 
[1,528]=4.98, p=0.026, partial ε2=0.009), sexuality needs (F 
[1,528]=6.76, p=0.010, partial ε2=0.013), BCS (F [1,528]=  
6.60, p=0.010, partial ε2=0.012), PWB (F [1,528]=10.28, 
p=0.001, partial ε2=0.019), and EWB (F [1,528]=4.88, p=  
0.028, partial ε2=0.009). According to post-hoc analyses, both 
depression and sexuality needs in the group receiving chemo-
therapy were statistically higher than those in the group not 
receiving chemotherapy (Figure 1). The quality of life sub-
scales including breast cancer subscale, physical well-being, 
and emotional well-being, on the other hand, were statistically 
higher in the group not receiving chemotherapy than in the 
group receiving chemotherapy (Figure 1).
The effects of chemotherapy on QOL variables according to 
time since surgery are summarized in Figure 2. Education, 
menstruation status, performance scale, hormone therapy, 
TNM stage, and time since surgery for group 1, TNM stage 
for group 2, and radiation therapy and TNM stage for group 3 
were identified as covariates, and hence, MANCOVA with 
each set of covariates were conducted. For group 1 (<1 year), 
postoperative chemotherapy had a statistically significant ef-
fect on depression (F [1,182]=3.29, p=0.042, partial ε2=  
0.018), unmet sexuality needs (F [1,182]=5.91, p=0.016, par-
tial ε2=0.031), BCS (F [1,182]=8.72, p=0.004, partial ε2=  
0.046), and PWB (F [1,182]=5.95, p=0.016, partial ε2=0.032). 
Post-hoc analyses indicated that both depression and sexuality 
needs in the group receiving chemotherapy were statistically 
higher than those in the group not receiving chemotherapy 
and that both BCS and PWB in women not receiving chemo-
therapy were statistically higher than those receiving chemo-
therapy. For group 2 (1-3 years since surgery), chemotherapy 
did not have a statistically significant effect on any of the meas-
ures. However, chemotherapy exhibited a statistically signifi-
cant effect on depression (F [1,179]=5.59, p=0.019, partial 
ε2=0.030) and PWB (F [1,179]=4.89, p=0.028, partial ε2=  
0.027) in group 3 (>3 years since surgery). As in the group 1, 
depression in women receiving chemotherapy was higher 
than those not receiving chemotherapy while PWB in women 
not receiving chemotherapy was higher than those receiving 
chemotherapy for group 3 (Figure 2).
DISCUSSION
In the present investigation, we examined the effects of ad-
juvant chemotherapy on QOL of women with breast cancer. 
We observed that women with past chemotherapy reported 
being more depressed, less satisfied with their life and having 
higher level of unmet sexuality needs than those without che-
motherapy. Furthermore, they experienced significantly poor 
physical, emotional, social/family, functional well-being and 
higher breast cancer specific concerns as measured by FACT-
B. The results of this study are in corroboration with previous 
reports [2,9,11], with additional new data on that women with 
past chemotherapy group suffers more difficulties in such an 
extensive area of QOL than women without chemotherapy 
group.
When the impact of adjuvant chemotherapy was analyzed 
according to survival time since surgery, chemotherapy was 
associated with poor QOL in group 1 (<1 year since surgery) 
and group 3 (>3 years since surgery). However, no statistical 
significance was observed in the group 2 (1-3 years since sur-
gery). Also women with past chemotherapy showed higher 
scores on BDI and unmet sexuality needs and lower scores in 
M
ea
n
BDI*
Sexuality
needs†
Global
QOL
BCS‡
PWB§
EWB|| FWB
SWB
30
25
20
15
10
5
0
Group A ( received chemotherapy) Group B ( not received chemotherapy)
Figure 1. Results of multiple analysis of covariance (MANCOVA) analy-
sis in Beck Depression Inventory (BDI), sexuality needs, global quality of 
life (QOL), and Functional Assessment Cancer Therapy-Breast (FACT-B). 
MANCOVA was performed after controlling for variables including per-
formance scale, TNM stage, hormone therapy, and time since surgery 
groups.
BDI=Beck Depression Inventory; QOL=quality of life; BCS=breast can-
cer subscale; PWB=physical well-being; EWB= emotional well-being; 
FWB=functional well-being; SWB=social well-being.
*Group A>Group B (p=0.026); †Group A>Group B (p=0.010); ‡Group 
A<Group B (p=0.010); §Group A<Group B (p=0.001); ||Group 
A<Group B (p=0.028).
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PWB and BCS than those with no chemotherapy in the group 
1 as women in this group possibly suffer short-term adverse 
effects of chemotherapy more directly. This confirms the pre-
vious findings and suggests the end of treatment period, 
known as ‘transition period’ and the treatment period itself is 
quite stressful [24]. While in a study by Ganz et al. [24], women 
with past chemotherapy at the end of treatment (ranged from 
21 to 471 days after surgery) reported worse physical and sex-
ual functioning but no statistically significant differences in 
mental health functioning including depression, our study 
participants with past chemotherapy in group 1 (<1 year) re-
ported being more depressive as well as having worse PWB 
and higher BCS and sexuality needs. This warrants further in-
vestigations focusing on association between chemotherapy 
and depression. Despite the effects of chemotherapy on sexual 
functioning is quite inconsistent depending on the tools used 
[11], it is quite meaningful that women receiving chemothera-
py in group 1 expressed significantly higher unmet sexual 
needs in our study, given the fact that Asian patients are more 
reluctant to talk about their sexual needs [25]. Oncologists 
might need to ask patients’ sexual functioning and psycholog-
ical distress related with chemotherapy treatment during their 
follow-up visits, in addition to their physical well-being. 
In contrary to above findings, the impact of chemotherapy 
was not found in group 2 (1-3 years since surgery). Patient in 
this group did not show any significant difference in QOL, 
global QOL, depression or unmet sexuality needs. It is reason-
able to assume that after 1 year of surgery, women receiving 
chemotherapy might be relatively relieved that not only che-
motherapy had been completed but the side effects of chemo-
therapy were significantly reduced, indicating their level of 
functioning have been quite recovered. Therefore, women 
with chemotherapy might have relatively good QOL during 
this time period, which can contribute to no QOL difference 
Figure 2. Results of multiple analysis of covariance (MANCOVA) analy-
sis according to time since surgery groups. MANCOVA for group 1 (A), 
group 2 (B), and group 3 (C) were performed after controlling for so-
ciodemographic and clinical variables (education, menopausal status, 
performance scale, hormone therapy, TNM stage, and time since sur-
gery [in months] for group 1; TNM stage for group 2; TNM stage and 
radiation therapy for group 3).
BDI=Beck Depression Inventory; QOL=quality of life; BCS=breast 
cancer subscale; PWB=physical well-being; EWB=emotional well-be-
ing; FWB=functional well-being; SWB=social well-being. 
*Group A>Group B (p=0.042); †Group A>Group B (p=0.016); ‡Group 
A<Group B (p=0.004); §Group A<Group B (p=0.016); ||Group 
A>Group B (p=0.019); ¶Group A<Group B (p=0.028).
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between chemotherapy group and no chemotherapy group. 
It is interesting to note that the difference of QOL, especially 
in terms of physical well-being and depression reappear in the 
group 3 (>3 years since surgery). Since the previous long-
term follow-up studies on the late effect of adjuvant chemo-
therapy are quite conflicting, one study suggested chemotherapy 
was associated with poorer physical, social and sexual func-
tioning in the long term follow-up [2], contrary to this, an an-
other study showed that past chemotherapy did not impair 
QOL [11]. However, our data confirms that the adverse effects 
of adjuvant chemotherapy on physical health and depression 
may persist or worsen 3 years after surgery. Given that women 
treated with chemotherapy might have worse prognosis than 
those with no chemotherapy, they may experience increased 
fear of recurrence as they realize still having chemotherapy re-
lated problems, and this might be reflected on significantly 
higher scores on the BDI. In addition to this, the results may 
also be related with the early menopausal symptoms. It is 
noteworthy to mention that the mean age of breast cancer pa-
tients in Korea is much younger than Western counterparts, 
with the prevalence being the highest in 40s (39.7%), followed 
by 50s (24.98%), and 30s (14.80%) [26]. Considering high 
proportion of premenopausal patients (the mean age in this 
study is 48.2±8.4 years in women receiving chemotherapy), 
the chemotherapy induced menopausal symptoms still persist 
even years after treatment reflecting in lower physical func-
tioning and higher level of depression.
Women who persistently depressed may be at risk of poor 
QOL and also vulnerable to premature death [27], which 
needs prompt professional psychological assessment and sup-
port. A long-term follow-up study suggested that the persis-
tent fatigue was also associated with depression [28]. Physical 
activity intervention may be an efficient intervention strategy 
[29,30] in addition to psychological intervention, which needs 
to be confirmed in future studies. 
It is important to recognize differences of QOL based on 
the various phases of survival time since surgery among che-
motherapy group as chemotherapy-related side effects may 
appear differently depending on time since surgery. Our re-
sults stress the need of health care professionals to monitor 
not only short-term adverse effects but also the long term ef-
fects of chemotherapy. 
The present study has several limitations. First, the impact 
of the adjuvant chemotherapy according to time since surgery 
can only be determined indirectly because of the cross-sec-
tional design. Second, the unmet sexuality needs measure 
evaluated only the needs not resolved without asking sexual 
functioning with partner directly, hence this study results can-
not be compared with those of other studies in terms of the 
chemotherapy effect on sexual functioning. Finally, the study 
participants were recruited from a single urban university 
hospital so the study results may not be generalized to all 
breast cancer patients in Korea. 
In conclusion, adjuvant chemotherapy for breast cancer sig-
nificantly affects QOL and the effects of chemotherapy on 
QOL appear to vary according to time since surgery. Breast 
cancer patients receiving chemotherapy experience the ad-
verse effects of adjuvant chemotherapy up to 1 year after sur-
gery on overall aspects of QOL and tend to recover later years. 
However, some negative impacts of chemotherapy on depres-
sion and physical well-being seem to reappear many years af-
ter surgery. Therefore, if future studies with a prospective de-
sign confirm our findings, we recommend that critical inter-
vention strategies should be designed to alleviate long-term as 
well as short-term chemotherapy side-effects for women with 
breast cancer. 
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